본문 바로가기
KERD
논문KCI 등재

전신성 항진균제와 임상적 이용

Systemic Antifungal Agents and Clinical Application

최상호|우준희|전재범|류지소
대한의진균학회 (The Korean Society for Medical Mycology)|2005.03|대한의진균학회지 (Journal of Mycology and Infection)|제10권 제1호|pp. 1-10

2

조회

0

다운로드

1

인용

0

참고문헌

주제분류미생물학

초록

전신성 진균감염에 대하여 개발된 항진균제로 이미 기술된 fluconazole, itraconazole을 제외한 ampho- tericin B lipid formulation인 AmB colloidal dispersion ([ABCD] Amphocil or Amphotec), AmB lipid complex ([ABLC] Abelcet), a small unilamellar vesicle liposomal formulation ([L-AmB] AmBisome)과 triazole계의 vori- conazole, ravuconazole, posaconazole 그리고 echino- candin계의 caspofungin, micafungin, anidulafungin의 약리학적 특성과 임상 적응증에 대하여 간략히 정리하였다.

Abstract

In the past, even two decades ago, it was not easy for the physicians to diagnose the systemic fungal infection especially in immuno-compromised host. However, as malignant neoplasm and organ transplantation increased, the incidence of fungal infection became heightened. Also the development of newer technique of microbiology and computerized imaging methods made it relatively easy to diagnose the fungal infection. Several new antifungal agents developed recently. It is necessary for us to prescribe the antifungal agents optimally. We summarized amphotericin B lipid formulations, newer triazoles, echinocandins

참고문헌 (45)

  1. "항바이러스약제와 항진균제", 32, pp.615~22 (1989)
  2. "전신성 진균감염증의 항균요법", 17, pp.414~417 (1974)
  3. "전신적 항진균제", 2, pp.110~122
  4. "새로운 항진균제", 8, pp.147~156 (2003)
  5. "Antimycotic properties of clotrimazole", 50, pp.11~12 (1974)
  6. "Azole antifungal agents:emphasis on new triazoles", 32, pp.1~8 (1988)
  7. "Resistance of Candida species to antifungal agents:molecular mechanisms and clinical consequences", 2, pp.73~85 (2002)
  8. "Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes", 8, pp.371~381 (1981)
  9. "Treatment of murine cryptococcosis with liposome-associated amphotericin B", 145, pp.748~752 (1982)
  10. "Amphotericin B in liposomes:a novel therapy for histoplasmosis", 125, pp.610~611 (1982)
  11. "Involvement of oxidative damage in erythrocyte lysis induced by amphotericin B", 27, pp.172~176 (1985)
  12. "Liposomal drug delivery.Advantages and limitations from a clinical pharmacokinetic and therapeutic perspective", 21, pp.155~164 (1991)
  13. "Lipid formulations of amphotericin B:recent progress and future directions", 22, pp.133~144 (1996)
  14. "and pharmacokinetics of high-dose liposomal amphotericin B in patients infected with Aspergillus species and other filamentous fungi", 45, pp.3487~3496
  15. "Antifungal drug resistance in pathogenic fungi", 1, pp.119~128 (1998)
  16. "A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients", 98, pp.711~718 (1997)
  17. "double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia", 31, pp.1155~1163
  18. "Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia.National Institute of Allergy and Infectious Diseases Mycoses Study Group", 340, pp.764~771 (1999)
  19. "Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS", 12, pp.2227~2228 (1998)
  20. "Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis", 347, pp.408~415 (2002)
  21. "Organism-dependent fungicidal activities of azoles", 42, pp.3018~3021 (1998)
  22. "Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes", 46, pp.3091~3093 (2002)
  23. "Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis", 34, pp.563~571 (2002)
  24. "multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients", 33, pp.1447~1454
  25. "Voriconazole in the treatment of aspergillosis,scedosporiosis and other invasive fungal infections in children", 21, pp.240~248 (2002)
  26. "Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever", 346, pp.225~234 (2002)
  27. "Voriconazole treatment for less-common,emerging,or refractory fungal infections", 36, pp.1122~1131 (2003)
  28. "In vitro activities of posaconazole and fluconazole against 37 clinical isolates of zygomycetes", 46, pp.1581~1582
  29. "In vitro susceptibilities of zygomycetes to conventional and new antifungals", 51, pp.45~52 (2003)
  30. "In vivo activity of posaconazole against Mucor spp.in an immunosuppressed-mouse model", 46, pp.2310~2312 (2002)
  31. "Newer systemic antifungal agents:pharmacokinetics,safety and efficacy", 64, pp.1997~2020 (2004)
  32. "A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis", 33, pp.1529~1535 (2001)
  33. "Prophylactic effect of FK463,a novel antifungal lipopeptide,against Pneumocystis carinii infection in mice", 44, pp.2259~2262 (2000)
  34. "In vitro activity of the new echinocandin antifungal,MK-0991,against common and uncommon clinical isolates of Candida species", 18, pp.302~304 (1999)
  35. "Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts", 36, pp.2950~2956
  36. "In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3 959 clinical isolates of Candida spp", 47, pp.1068~1071, including 157 fluconazole-resistant isolates
  37. "Antifungal susceptibility of Candida biofilms:unique efficacy of amphotericin B lipid formulations and echinocandins", 46, pp.1773~1780 (2002)
  38. "Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis", 42, pp.873~878 (1998)
  39. "Randomized,double-blind,multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases", 46, pp.451~457 (2002)
  40. "Resolution of multidrug-refractory oesophageal candidiasis in an AIDS patient after treatment with caspofungin 2002", 16, pp.1303~1304
  41. "Comparison of caspofungin and amphotericin B for invasive candidiasis", 347, pp.2020~2029 (2002)
  42. "Caspofungin", 36, pp.1445~1457 (2003)
  43. "In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients", 50, pp.119~123 (2002)
  44. "Synergy,pharmacodynamics,and time sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus", 45, pp.3310~3321 (2001)
  45. "Combination therapy in treatment of experimental pulmonary aspergillosis:synergistic interaction between an antifungal triazole and an echinocandin", 187, pp.1834~1843 (2003)

관련 논문AI추천

새로운 항진균제와 임상적 적용백경란대한의진균학회 · 대한의진균학회지2005 · 제10권 제4호새로운 항진균제의 국내 사용 및 전망강문원, 김상일대한감염학회 · Infection and Chemotherapy2010 · 제42권 제4호칸디다 균종의 Caspofungin과 Micafungin에 대한 생체 외 감수성 성적조덕, 서순팔, 신명근, 신종희, 양동욱, 이진솔, 최현우대한진단검사의학회 · Annals of Laboratory Medicine2006 · 제26권 제4호주요 효모균과 사상형 진균의 항진균제 내성현황신종희대한감염학회 · Infection and Chemotherapy2009 · 제41권 제2호항진균제 감수성 검사의 최신지견: 검사법과 임상적 이용신종희대한임상미생물학회 · Annals of Clinical Microbiology2009 · 제12권 제4호침습성 진균 감염증과 약제 내성김어진, 정숙인대한내과학회 · 대한내과학회지2015 · 제88권 제5호

이 간행물의 다른 논문 (4건)

지속적으로 열이 나는 호중구감소증 환자에 대한경험적 항진균제 치료오명돈, 최강원, 이창섭pp. 11-20선형 조갑진균증의 발생 요인과 치료 반응에 대한 연구김정수, 유희준, 오대헌, 은철pp. 21-29조갑진균증의 진단 방법으로서 조갑판 PAS 염색 및GMS 염색의 유용성에 대한 연구김일환, 전지현pp. 30-34지간 백선 1예임재우, 서무규, 이용환, 하경임, 권순욱pp. 35-38
원문 보기